MX392514B - Vacuna para estreptococo del grupo a. - Google Patents
Vacuna para estreptococo del grupo a.Info
- Publication number
- MX392514B MX392514B MX2016013277A MX2016013277A MX392514B MX 392514 B MX392514 B MX 392514B MX 2016013277 A MX2016013277 A MX 2016013277A MX 2016013277 A MX2016013277 A MX 2016013277A MX 392514 B MX392514 B MX 392514B
- Authority
- MX
- Mexico
- Prior art keywords
- group
- spycep
- fragment
- protein
- mammal
- Prior art date
Links
- 241001505901 Streptococcus sp. 'group A' Species 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 2
- 108010033276 Peptide Fragments Proteins 0.000 abstract 2
- 102000007079 Peptide Fragments Human genes 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 101710085938 Matrix protein Proteins 0.000 abstract 1
- 101710127721 Membrane protein Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 210000000440 neutrophil Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2014901382A AU2014901382A0 (en) | 2014-04-15 | Group a streptococcal vaccine | |
| AU2014903042A AU2014903042A0 (en) | 2014-08-06 | Group a streptococcal vaccine | |
| AU2014904453A AU2014904453A0 (en) | 2014-11-05 | Group a streptococcal vaccine | |
| PCT/AU2015/050174 WO2015157820A1 (en) | 2014-04-15 | 2015-04-15 | Group a streptococcus vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016013277A MX2016013277A (es) | 2017-01-18 |
| MX392514B true MX392514B (es) | 2025-03-24 |
Family
ID=54323282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016013277A MX392514B (es) | 2014-04-15 | 2015-04-15 | Vacuna para estreptococo del grupo a. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10301362B2 (enExample) |
| EP (1) | EP3131575B1 (enExample) |
| JP (2) | JP2017513849A (enExample) |
| KR (2) | KR102730367B1 (enExample) |
| CN (1) | CN106794236B (enExample) |
| AU (1) | AU2015246654B2 (enExample) |
| BR (1) | BR112016023915B1 (enExample) |
| CA (1) | CA2945052C (enExample) |
| DK (1) | DK3131575T3 (enExample) |
| IL (1) | IL248266B (enExample) |
| MX (1) | MX392514B (enExample) |
| MY (1) | MY191217A (enExample) |
| NZ (1) | NZ725212A (enExample) |
| SG (1) | SG11201608380PA (enExample) |
| WO (1) | WO2015157820A1 (enExample) |
| ZA (1) | ZA201607355B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY191217A (en) | 2014-04-15 | 2022-06-09 | Univ Griffith | Group a streptococcus vaccine |
| CN106606775A (zh) * | 2015-10-27 | 2017-05-03 | 格里菲斯大学 | 脂质体a群链球菌疫苗 |
| TWI598360B (zh) * | 2016-12-19 | 2017-09-11 | 義守大學 | Ｆｓｂｍ重組蛋白及其用途 |
| CN111344007A (zh) * | 2017-08-23 | 2020-06-26 | 格里菲斯大学 | 抗a组链球菌的免疫原性肽 |
| CN110776508B (zh) * | 2018-07-27 | 2021-07-16 | 海创药业股份有限公司 | 一种brd4抑制剂及其制备方法和用途 |
| KR102437436B1 (ko) * | 2019-04-26 | 2022-08-30 | 주식회사 엠디헬스케어 | 스트렙토코커스 파이오제네스 세균 유래 단백질 및 이의 용도 |
| NL2023863B1 (en) | 2019-09-20 | 2021-05-25 | Univ Griffith | Protein particles and uses thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5047238A (en) | 1983-06-15 | 1991-09-10 | American Home Products Corporation | Adjuvants for vaccines |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5811105A (en) | 1987-12-23 | 1998-09-22 | Glaxo Wellcome, Inc. | Vaccines containing bacteria attenuated by mutations in two genes of the aromatic amino acid biosynthetic pathway |
| US5785973A (en) | 1988-02-01 | 1998-07-28 | Praxis Biologics, Inc. | Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines |
| GB8912330D0 (en) | 1989-05-30 | 1989-07-12 | Wellcome Found | Live vaccines |
| GB9007194D0 (en) | 1990-03-30 | 1990-05-30 | Wellcome Found | Live vaccines |
| AUPM885194A0 (en) * | 1994-10-14 | 1994-11-10 | Council Of The Queensland Institute Of Medical Research, The | Synthetic peptides and vaccines comprising same |
| AUPO007396A0 (en) | 1996-05-24 | 1996-06-20 | Csl Limited | Ebv ctl epitopes |
| AUPO784197A0 (en) | 1997-07-10 | 1997-08-07 | Csl Limited | Treatment of nasopharyngeal carcinoma |
| AU2005294275B2 (en) * | 2004-10-08 | 2012-09-13 | Glaxosmithkline Biologicals S.A. | Immunogenic and therapeutic compositions for Streptococcus pyogenes |
| EP1879613B1 (en) * | 2005-05-05 | 2011-11-30 | Merck Sharp & Dohme Corp. | Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease |
| EP1962961B1 (en) | 2005-11-29 | 2013-01-09 | The University Of Sydney | Demibodies: dimerisation-activated therapeutic agents |
| AU2007271350B2 (en) * | 2006-07-07 | 2013-03-21 | Intercell Ag | Small Streptococcus pyogenes antigens and their use |
| US20090010929A1 (en) | 2006-12-04 | 2009-01-08 | Good Michael F | Therapeutic Antibodies, Antibody Fragments and Antibody Conjugates |
| US8482298B2 (en) | 2006-12-18 | 2013-07-09 | Schrader Electronics Ltd. | Liquid level and composition sensing systems and methods using EMF wave propagation |
| CA2699513C (en) * | 2007-09-12 | 2018-03-13 | Novartis Ag | Gas57 mutant antigens and gas57 antibodies |
| US20090162369A1 (en) * | 2007-12-12 | 2009-06-25 | Katin Helena Threse Nordstrom | Synthetic chimeric peptides |
| JP5680536B2 (ja) | 2008-09-17 | 2015-03-04 | ノバルティス アーゲー | 組み合わせｇａｓワクチンおよび治療法 |
| MY191217A (en) | 2014-04-15 | 2022-06-09 | Univ Griffith | Group a streptococcus vaccine |
| CN111344007A (zh) * | 2017-08-23 | 2020-06-26 | 格里菲斯大学 | 抗a组链球菌的免疫原性肽 |
-
2015
- 2015-04-15 MY MYPI2016001815A patent/MY191217A/en unknown
- 2015-04-15 NZ NZ725212A patent/NZ725212A/en unknown
- 2015-04-15 KR KR1020167031477A patent/KR102730367B1/ko active Active
- 2015-04-15 KR KR1020237007349A patent/KR102744193B1/ko active Active
- 2015-04-15 WO PCT/AU2015/050174 patent/WO2015157820A1/en not_active Ceased
- 2015-04-15 CN CN201580027379.8A patent/CN106794236B/zh active Active
- 2015-04-15 EP EP15779482.7A patent/EP3131575B1/en active Active
- 2015-04-15 JP JP2016562764A patent/JP2017513849A/ja active Pending
- 2015-04-15 SG SG11201608380PA patent/SG11201608380PA/en unknown
- 2015-04-15 BR BR112016023915-6A patent/BR112016023915B1/pt active IP Right Grant
- 2015-04-15 AU AU2015246654A patent/AU2015246654B2/en active Active
- 2015-04-15 MX MX2016013277A patent/MX392514B/es unknown
- 2015-04-15 DK DK15779482.7T patent/DK3131575T3/da active
- 2015-04-15 CA CA2945052A patent/CA2945052C/en active Active
- 2015-04-15 US US15/304,462 patent/US10301362B2/en active Active
-
2016
- 2016-10-09 IL IL248266A patent/IL248266B/en unknown
- 2016-10-25 ZA ZA2016/07355A patent/ZA201607355B/en unknown
-
2019
- 2019-04-30 US US16/398,598 patent/US10513544B2/en active Active
-
2020
- 2020-12-03 JP JP2020201171A patent/JP7072921B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3131575B1 (en) | 2024-05-08 |
| BR112016023915A2 (pt) | 2017-10-17 |
| JP2021042247A (ja) | 2021-03-18 |
| MX2016013277A (es) | 2017-01-18 |
| EP3131575A4 (en) | 2017-11-01 |
| CA2945052C (en) | 2023-05-02 |
| JP2017513849A (ja) | 2017-06-01 |
| BR112016023915B1 (pt) | 2024-03-12 |
| KR102744193B1 (ko) | 2024-12-19 |
| JP7072921B2 (ja) | 2022-05-23 |
| CA2945052A1 (en) | 2015-10-22 |
| CN106794236B (zh) | 2021-09-03 |
| DK3131575T3 (da) | 2024-05-21 |
| KR20160144455A (ko) | 2016-12-16 |
| ZA201607355B (en) | 2019-03-27 |
| EP3131575A1 (en) | 2017-02-22 |
| US10513544B2 (en) | 2019-12-24 |
| SG11201608380PA (en) | 2016-11-29 |
| US20170037087A1 (en) | 2017-02-09 |
| WO2015157820A1 (en) | 2015-10-22 |
| KR102730367B1 (ko) | 2024-11-15 |
| CN106794236A (zh) | 2017-05-31 |
| MY191217A (en) | 2022-06-09 |
| KR20230039751A (ko) | 2023-03-21 |
| US20190256562A1 (en) | 2019-08-22 |
| NZ725212A (en) | 2023-04-28 |
| US10301362B2 (en) | 2019-05-28 |
| AU2015246654A1 (en) | 2016-11-03 |
| IL248266B (en) | 2021-09-30 |
| IL248266A0 (en) | 2016-11-30 |
| AU2015246654B2 (en) | 2019-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX392514B (es) | Vacuna para estreptococo del grupo a. | |
| CY1123163T1 (el) | Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων | |
| IL270090B (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
| IL255106A0 (en) | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof | |
| IL263846B (en) | Formulation of a peptide vaccine | |
| AR101845A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
| MX362456B (es) | Anticuerpos y vacunas para utilizarse en el tratamiento de canceres por ror1 y para inhibir la metastasis. | |
| EA201790239A1 (ru) | Молекула-носитель для антигенов | |
| MX2017008186A (es) | Anticuerpos humanos para la hemaglutinina de influenza. | |
| MX375524B (es) | Anticuerpos anti-axl. | |
| EA201692512A1 (ru) | Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки | |
| MX2017005977A (es) | Anticuerpos biespecificos y metodos de uso en oftalmologia. | |
| MY191539A (en) | Streptococcal vaccine | |
| BR112017011556A2 (pt) | métodos para gerar um anticorpo sintético, prevenir ou tratar uma doença, tratar um sujeito de infecção por um patógeno e um sujeito com câncer, produto, molécula de ácido nucleico, e, composição. | |
| EA201590829A1 (ru) | Новые мукозные адъюванты и системы доставки | |
| BR112017023131A2 (pt) | anticorpos anti- fcrn | |
| MX2016005956A (es) | Anticuerpos especificos para fcrn. | |
| MX2017003121A (es) | Formulaciones de anticuerpos. | |
| MX2014006630A (es) | Vacuna a base toxina clostridium difficile. | |
| AR090668A1 (es) | Anticuerpo anti-adamts-5, derivados y usos del mismo | |
| MX2016014868A (es) | Metodos para secar por congelacion y rehidratar productos biologicos. | |
| MX380411B (es) | Sistema de marcadores, en particular para antigenos subunitarios expresados por baculovirus. | |
| CU20170012A7 (es) | Anticuerpos anti proteína similar a angiopoyetina 4 | |
| DK3523653T3 (da) | Rep-protein som protein-antigen til brug i diagnostiske analyser | |
| UY36617A (es) | Proteínas de fusión inmunogénicas para el tratamiento del cáncer |